Isolated liver chemoperfusion in a patient with mesenteric leiomyosarcoma and liver metastasis

• Published in: Sibirskiĭ onkologicheskiĭ zhurnal Vol. 23; no. 2; pp. 126 - 132
• Main Authors: Reshetov, I. V., Manukovsky, V. A., Demko, A. E., Cheremisov, V. V., Osipov, A. V., Taniya, S. Sh, Privalov, M. A., Babich, A. I.
• Format: Journal Article
• Language: English; Russian
• Published: Russian Academy of Sciences, Tomsk National Research Medical Center 12.05.2024
• Subjects: isolated liver melphalan chemoperfusion; leiomyosarcoma; metastatic liver tumors
• ISSN: 1814-4861; 2312-3168
• DOI: 10.21294/1814-4861-2024-23-2-126-132

Background . Treatment for inoperable secondary liver cancer remains challenging especially in patients with colorectal cancer. Traditional systemic drug therapy is often ineffective, and the use of transarterial chemoembolization is limited due to the systemic toxicity of some drugs. Combining high efficacy and low systemic toxicity, isolated chemoperfusion is a promising treatment option for patients with liver metastasis. Case report . A patient with mesentery leiomyosarcoma underwent several surgeries and chemotherapy courses, but liver metastases continued to grow. Isolated liver chemoperfusion with melphalan was performed after resection of liver segment and mobilization of liver vessels. To reduce the tumor volume and prevent complications, atypical liver resection was also performed. Conclusion . Isolated liver chemoperfusion for the treatment of liver cancer remains a subject of debate and is not included in the standards for treatment of primary and metastatic liver tumors. This technique was shown to be safe and promising in treating liver metastasis from leiomyosarcoma. However, further research is required to assess the role of this procedure in overall survival.